XEN®-45 implantation for refractory uveitic glaucoma

• DOI: 10.1007/s00417-023-06254-3
• Publication Date: 2023-10-19T10:03:30Z
• Authors: Charlotte Evers; Alexandra Anton; Daniel Böhringer; Sara Kallee; Philip Keye; Thomas Neß; Heiko Philippin; Thomas Reinhard; Jan Lübke
• Keywords: Glaucoma medication; Glaucoma surgery; Refractory (planetary science); Acetazolamide

Abstract Purpose To evaluate the efficacy of XEN ® -45 gel stent ab interno implantation for medically uncontrolled uveitic glaucoma. Methods Retrospective analysis 25 eyes receiving glaucoma from February 2019 to 2023 with recording intraocular pressure (IOP) values, ocular hypotensive medication, requirement revision or secondary surgery and complications. Prerequisites were a clear cornea, an open iridocorneal angle unscarred, mobile conjunctiva at site. Minimum follow-up required inclusion was 3 months. The primary outcome measure IOP compared baseline. Complete qualified success defined as final ≤ 18 mmHg without topical antiglaucomatous treatment, respectively. Failure > on two consecutive visits, reduction < 20%, persisting complications hypotony conjunctival bleb revision. Further surgical intervention complete failure. Results Mean preoperative 35.3 ± 10.9 2.9 0.9 agents. 19 patients (76%) received additional oral acetazolamide. pseudophakic, 5 phakic 1 aphakic. Early postoperatively, mean reduced 7.7 3.0 (75.8% reduction). At (mean 17.7 months) 12.0 3.8 (62.5% reduction) 0.2 0.6 medications. Six (24%) 28 weeks therefore categorized One eye failed despite restart medication. Three other (12%) had spikes uveitis flare-ups. Transient occurred in 32%. follow-up, (72%) achieved one (4%) success. Conclusion effectively glaucoma, 72% Bleb 24%. 12% functioning blebs. is needed determine long-term outcomes.